A 52-year-old man from Delhi presents with a 3-month history of progressive jaundice, abdominal pain, and weight loss of 8 kg. On examination, he has hepatomegaly and a palpable epigastric mass. Ultrasound shows a 4 cm hypoechoic lesion in the pancreatic head with dilated intrahepatic bile ducts. Serum bilirubin is 8.2 mg/dL (direct 6.8 mg/dL). CA 19-9 level is 450 U/mL (normal <37 U/mL). Which of the following statements about CA 19-9 in this clinical context is most accurate?

Explanation

## CA 19-9 in Pancreatic Cancer ### Clinical Role of CA 19-9 **Key Point:** CA 19-9 is a sialylated Lewis antigen (carbohydrate antigen) that is elevated in pancreatic adenocarcinoma but lacks diagnostic specificity. **High-Yield:** CA 19-9 is elevated in: - Pancreatic cancer (60–80% of cases) - Cholangiocarcinoma - Gastric cancer - Colorectal cancer - Benign conditions: pancreatitis, cirrhosis, cholecystitis, biliary obstruction ### Uses in Clinical Practice | Use | Role | Evidence | |-----|------|----------| | **Diagnosis** | NOT diagnostic alone; must be combined with imaging | Lacks specificity; elevated in benign biliary obstruction | | **Prognosis** | Elevated levels correlate with advanced disease and poor prognosis | Prognostic marker at baseline | | **Monitoring** | Serial measurement tracks treatment response and recurrence | Most useful application; falling levels suggest response | | **Screening** | NOT recommended for population screening | Low sensitivity in early disease; too many false positives | ### Why CA 19-9 is Useful Here In this patient with imaging-confirmed pancreatic mass and jaundice: - CA 19-9 **supports** the diagnosis (though imaging is definitive) - Baseline level **predicts prognosis** (450 U/mL indicates advanced disease) - Serial CA 19-9 will **monitor chemotherapy response** or recurrence post-surgery **Clinical Pearl:** CA 19-9 is **not** elevated in 10–15% of pancreatic cancers (Lewis antigen-negative patients), so a normal value does not exclude cancer. **Warning:** Benign biliary obstruction (as in this case) can also elevate CA 19-9; imaging is required to distinguish cancer from obstruction. ### Limitations - **No diagnostic specificity:** Cannot be used alone to diagnose pancreatic cancer - **Not for screening:** High false-positive rate in asymptomatic populations - **Limited in early disease:** Sensitivity is low in localized, resectable tumors - **Affected by benign conditions:** Pancreatitis, cholecystitis, and biliary obstruction can elevate it [cite:Robbins 10e Ch 20]